MONTCLAIR, NJ -- (MARKETWIRE) -- 02/28/13 -- FluoroPharma Medical, Inc. (OTCBB: FPMI), a company specializing in the development of novel diagnostic imaging products that utilize positron emission tomography (PET) technology for the detection and assessment of disease before clinical manifestation, today released images from the Phase II clinical trial for CardioPET™ (FCPHA) to assess myocardial perfusion and fatty acid uptake in coronary artery disease (CAD) patients.
CardioPET, one of FluoroPharma's first in class PET imaging products, is a perfusion and fatty acid uptake indicator, which is designed to be used as a cardiac imaging agent and may be a more specific alternative to currently available diagnostic tests. Management believes its pharmacokinetic characteristics could be especially valuable in patients who are unable to exercise.
The Phase II trial is an open label study designed to assess the safety and diagnostic performance of CardioPET as compared with myocardial perfusion imaging and angiography, the current gold standard. Trial sites are located in Belgium and results continue to be expected over the next six months.
According to Prof. Roland Hustinx, one of the investigators in the trial and head of nuclear medicine at the University Hospital in Liege, "The images obtained from CardioPET are high quality and agree with previous clinical findings."